Visit COVID-19 resources

[Skip to Content]

RVO

NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal

Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual

Clinical Guidelines

Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare for specific eye disorders, enhancing clinician and patient decision making by describing and appraising the scientific evidence and reasoning behind clinical recommendations. They are developed to make recommendations for the majority of clinical situations; however they are intended as an aid

Intravitreal Ranibizumab injection for treatment of MO secondary to RVO

College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either